Humantenmine

CAS No. 82354-38-9

Humantenmine( —— )

Catalog No. M19144 CAS No. 82354-38-9

Humantenmine and koumine may inhibit several CYP450 enzyme activities.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 132 In Stock
5MG 136 In Stock
10MG 217 In Stock
25MG 370 In Stock
50MG 538 In Stock
100MG 770 In Stock
200MG 1051 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Humantenmine
  • Note
    Research use only, not for human use.
  • Brief Description
    Humantenmine and koumine may inhibit several CYP450 enzyme activities.
  • Description
    Humantenmine is a toxic compound isolated from Gelsemium elegans Benth. Humantenmine and koumine may inhibit several CYP450 enzyme activities.
  • In Vitro
    Humantenmine (HMT) decreases the 14-day survival rate of the mice to 17% after they are intragastrically treated with HMT, along with hepatic injury and increasing alanine aminotransferase (ALT)/aspartate aminotransferase (AST) levels. CYP3A4/5 mediates the metabolism and detoxification of HMT.
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Membrane Transporter/Ion Channel
  • Target
    Beta Amyloid
  • Recptor
    CYP450
  • Research Area
    Others-Field
  • Indication
    ——

Chemical Information

  • CAS Number
    82354-38-9
  • Formula Weight
    326.39
  • Molecular Formula
    C19H22N2O3
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (306.38 mM)
  • SMILES
    CCC1=NC2CC3(C4CC1C2CO4)C5=CC=CC=C5N(C3=O)OC
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Scyllo-Inositol

    Scyllo-Inositol is one of the inositol stereoisomers rare in the nature and expected as a promising disease-modifying therapeutic agent for Alzheimer's disease.

  • V-9-M Cholecystokini...

    V-9-M Cholecystokinin nonapeptide (Prepro CCK Fragment V-9-M) is a precursor compound of cholecystokinin (CCK).

  • Solanezumab

    Solanezumab (LY 2062430) is a monoclonal antibody that binds preferentially to soluble amyloid and promotes its clearance from the brain.Solanezumab is used in the study of Alzheimer's disease.